Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Roducitabine · RX-3117, TV-1360

Small molecule · Cytotoxic, directed at DNA methyltransferase 1 (DNMT1) · developed by Processa Pharmaceuticals

Phase 1/2 Most advanced trial (none active)
PCSA Developer
1 Registered trials

What is Roducitabine?

Roducitabine is an orally available nucleoside antimetabolite that is phosphorylated by uridine cytidine kinase and incorporated into RNA and DNA, inhibiting RNA synthesis and also inhibiting DNA methyltransferase 1. It is studied in solid tumors and metastatic bladder cancer.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
RX-3117, TV-1360
Drug type
Small molecule
Targets
DNA methyltransferase 1 (DNMT1) (secondary target), ribonucleotide reductase (binding partner it blocks)
Mechanism
Cytotoxic, directed at DNA methyltransferase 1 (DNMT1)
Pathways
RNA synthesis inhibition, DNA incorporation and synthesis disruption, pyrimidine-nucleotide salvage pathway, cell cycle arrest, apoptosis
Therapy area
Oncology
Developer
Processa Pharmaceuticals (PCSA)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1/2
UNII
0Z4A82I0JO

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT02030067 Phase 1/2 Solid Tumor Completed PCSA

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Metastatic Bladder CancerSolid Tumor

Other drugs acting on DNMT1

More from Processa Pharmaceuticals

Sources

Updated Oct 25, 2026. Something wrong or missing? Report it on the PCSA page.

Follow PCSA, the company behind Roducitabine

See PCSA's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

PCSA catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.